<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE" />
<meta name="dc.language" content="eng" />
<meta name="dc.title" content="Taylor v. Canada (Attorney General), 2012 ONCA 479" />	
<meta name="dc.date.created" content="2012-07-06" />
<meta name="dc.date.modified" content="2012-07-06" />
<title>Taylor v. Canada (Attorney General), 2012 ONCA 479</title>
<style>
<!--
h1 { line-height:200%; page-break-after:avoid; font-size:13.0pt; font-family:"Arial", "sans-serif"; text-transform:uppercase; }
h2 { line-height:200%; page-break-after:avoid; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
h3 { line-height:200%; page-break-after:avoid; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
h4 { text-indent:0in; line-height:200%; page-break-after:avoid; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
h5 { line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
h6 { line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7 { line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; }
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8 { line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; }
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9 { line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; }
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText { font-size:10.0pt;	font-family:"Arial", "sans-serif"; }
span.MsoPageNumber { font-family:"Arial", "sans-serif"; }
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet { text-align:justify; line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst { text-align:justify; line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle { text-align:justify; line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast { text-align:justify; line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2 { text-align:justify; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText { font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.MsoDate, li.MsoDate, div.MsoDate { font-size:13.0pt; font-family:"Arial", "sans-serif"; }
em { font-family:"Arial", "sans-serif"; }
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate { font-size:8.0pt; font-family:"Arial", "sans-serif"; }
span.MsoPlaceholderText { color:gray; }
span.Heading1Char { font-family:"Arial", "sans-serif"; text-transform:uppercase; font-weight:bold; }
span.Heading2Char { font-family:"Arial", "sans-serif"; font-weight:bold; }
span.Heading3Char { font-family:"Arial", "sans-serif"; font-weight:bold; }
span.Heading4Char { font-family:"Arial", "sans-serif"; font-weight:bold; }
span.Heading5Char { font-family:"Arial", "sans-serif"; font-weight:bold; }
span.Heading6Char { font-family:"Arial", "sans-serif"; font-weight:bold; }
span.Heading7Char { font-family:"Arial", "sans-serif"; font-weight:bold; }
span.Heading8Char { font-family:"Arial", "sans-serif"; font-weight:bold; }
span.Heading9Char { font-family:"Arial", "sans-serif"; font-weight:bold; }
p.CITATION, li.CITATION, div.CITATION { text-align:right; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.DATE, li.DATE, div.DATE { text-align:right; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
span.DateChar { font-family:"Arial", "sans-serif"; }
p.DOCKET, li.DOCKET, div.DOCKET { text-align:right; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.CourtofAppealforOntario, li.CourtofAppealforOntario, div.CourtofAppealforOntario { text-align:center; font-size:15.0pt; font-family:"Arial", "sans-serif"; }
p.Namesofpanelofjudges, li.Namesofpanelofjudges, div.Namesofpanelofjudges { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
span.BalloonTextChar { font-family:"Arial", "sans-serif"; }p.BETWEEN, li.BETWEEN, div.BETWEEN { font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Namesofparty, li.Namesofparty, div.Namesofparty { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Partys, li.Partys, div.Partys { text-align:right; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.and, li.and, div.and { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Nameofcounsel, li.Nameofcounsel, div.Nameofcounsel { font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Heard, li.Heard, div.Heard { font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Onappealfrom, li.Onappealfrom, div.Onappealfrom { text-align:justify; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Judge, li.Judge, div.Judge { font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; }
span.Underline { font-family:"Arial", "sans-serif"; text-decoration:underline; }
p.StrongUnderline, li.StrongUnderline, div.StrongUnderline { font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; text-decoration:underline; }
p.DSubquote, li.DSubquote, div.DSubquote { text-align:justify; margin-left: 5%; margin-right: 5%;font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.AParaNumbering, li.AParaNumbering, div.AParaNumbering { text-align:justify; text-indent:0in; line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
span.BodyTextChar { font-family:"Arial", "sans-serif"; }
p.CQuote, li.CQuote, div.CQuote { text-align:justify; margin-left: 5%; margin-right: 5%;font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.BContinuingPara, li.BContinuingPara, div.BContinuingPara { text-align:justify; line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
span.FootnoteTextChar { font-family:"Arial", "sans-serif"; }
p.LHeading11, li.LHeading11, div.LHeading11 { line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; font-style:italic; }
span.LHeading11Char { font-family:"Arial", "sans-serif"; font-weight:bold; font-style:italic; }
p.KHeading10, li.KHeading10, div.KHeading10 {  line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; }
p.MHeading12, li.MHeading12, div.MHeading12 { text-align:center; text-indent:0in; line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; }p.EmphasisStrong, li.EmphasisStrong, div.EmphasisStrong { font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; font-style:italic; }
p.LegislativeQuote, li.LegislativeQuote, div.LegislativeQuote { text-align:justify; margin-left: 5%; margin-right: 5%;font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.LegislativeSubquote, li.LegislativeSubquote, div.LegislativeSubquote { text-align:justify; margin-left: 10%;  margin-right: 10%; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.FootnoteTextEmphasis, li.FootnoteTextEmphasis, div.FootnoteTextEmphasis { font-size:10.0pt; font-family:"Arial", "sans-serif"; font-style:italic; }
p.Heading, li.Heading, div.Heading { line-height:200%; font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; }
p.EmphasisUnderline, li.EmphasisUnderline, div.EmphasisUnderline { font-size:13.0pt; font-family:"Arial", "sans-serif"; font-style:italic; text-decoration:underline; }
p.EmphasisStrongUnderline, li.EmphasisStrongUnderline, div.EmphasisStrongUnderline { font-size:13.0pt; font-family:"Arial", "sans-serif"; font-weight:bold; font-style:italic; text-decoration:underline; }
span.EmphasisUnderlineChar { font-family:"Arial", "sans-serif"; font-style:italic; text-decoration:underline; }span.FootnoteTextEmphasisChar { font-family:"Arial", "sans-serif"; font-style:italic; }
span.EmphasisStrongUnderlineChar { font-family:"Arial", "sans-serif"; font-weight:bold; font-style:italic; text-decoration:underline; }
span.DSubquoteChar { font-family:"Arial", "sans-serif"; }
.MsoChpDefault { font-size:13.0pt; }
div.Section1 { page:Section1; }
p.Endorsement { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Endorsment { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.OralEndorsement { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.AppealBookEndorsement { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.APPEALBOOKENDORSEMENT { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Costs { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.COSTSENDORSEMENT { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.CostsEndorsement { text-align:center; font-size:13.0pt; font-family:"Arial", "sans-serif"; }
p.Warning  { text-align:center; font-weight:bold; font-size:14.0pt; font-family:"Arial", "sans-serif"; }
p  { font-size:13.0pt; font-family:"Arial", "sans-serif"; }
-->
</style>
</HEAD>
<body bgcolor="#FFFFFF" lang=EN-CA>
<div class=Section1>
  <p class=CourtofAppealforOntario>COURT OF APPEAL FOR ONTARIO</p>
  <p class=CITATION>CITATION:&nbsp;<a name="OLE_LINK8"></a><a name="OLE_LINK7">Taylor&nbsp;v.&nbsp;Canada
    (Attorney General),&nbsp;2012 ONCA 479</a></p>
  <p class=CITATION>DATE:  20120706</p>
  <p class=DOCKET>DOCKET: C53678</p>
  <p class=Namesofpanelofjudges>Doherty, Weiler, Laskin, Sharpe and Armstrong
    JJ.A.</p>
  <p class=BETWEEN>BETWEEN</p>
  <p class=Namesofpanelofjudges>Kathryn Anne Taylor</p>
  <p class=Partys>Plaintiff </p>
  <p class=and>and</p>
  <p class=Namesofpanelofjudges>The Attorney General of Canada</p>
  <p class=Partys>Defendant </p>
  <p class=Nameofcounsel>Kirk Baert and Celeste Poltak, for the plaintiff</p>
  <p class=Nameofcounsel>P.J. Evraire, Q.C., Gina M. Scarcella and James M.
    Soldatich, for the defendant</p>
  <p class=Nameofcounsel>Cameron Pallett and Reynold Robertson, for the
    intervener, Bill Sauer</p>
  <p class=Heard>Heard: September 19, 2011</p>
  <p class=Onappealfrom>A proceeding under Rule 22.03 to determine a special case
    stated by order of Armstrong J.A. dated March 4, 2011, with reasons reported at
    2011 ONCA 181.</p>
  <p class=Judge><strong><span style='font-family:"Arial","sans-serif"'>Doherty
    J.A.:</span></strong></p>
  <p class=AParaNumbering>[1]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Government
    regulation impacts on most facets of modern life, particularly matters of
    public health and safety. If a government regulator exercises its powers in a
    negligent way, people can be hurt and suffer substantial damages. The question
    in this proceeding, and it is far from a novel or easy one, is when does the
    regulator owe a <em>prima facie</em> private law duty of care to the individual
    harmed by the regulator’s negligence? </p>
  <p class=MHeading12><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>I<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span> </p>
  <h1>THE Nature of thIS proceeding</h1>
  <p class=AParaNumbering>[2]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>This
    is not an appeal. This matter comes before the court as a special case stated
    under Rule 22.03 of the <em>Rules of Civil Procedure</em>, R.R.O. 1990, Reg.
    194. The stated case poses two questions:</p>
  <p class=MsoListBulletCxSpFirst>1)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>What are the
    requirements in a statement of claim to establish sufficient proximity between
    the plaintiff and the defendant in a claim brought against a governmental body
    for regulatory negligence?</p>
  <p class=MsoListBulletCxSpLast>2)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Does the amended
    statement of claim in this action satisfy those requirements?</p>
  <p class=AParaNumbering>[3]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
    special case procedure is an unusual one. Resort to it is justified in this
    instance by the apparent inconsistency in this court’s jurisprudence, the
    tortured and lengthy procedural history of this case, and the importance of the
    legal issue raised by the first of the two questions posed. The jurisprudential
    inconsistency is said to arise from this court’s reasons in <em>Drady v. Canada
    (Minister of Health)</em><em><span style='font-style:normal'>, 2008 ONCA 659,
    300 D.L.R. (4th) 443, leave to appeal to S.C.C. refused, [2008] S.C.C.A. No.
    492,</span></em><i> </i>and <em>Attis v. Canada (Minister of Health)</em><em><span
style='font-style:normal'>, 2008 ONCA 660, 93 O.R. (3d) 35, leave to appeal to
    S.C.C. refused, [2008] S.C.C.A. No. 491,</span></em> on the one hand, and <em>Sauer
    v. Canada (AG)</em><em><span style='font-style:normal'>, 2007 ONCA 454, 225
    O.A.C. 143, leave to appeal to S.C.C. refused, [2007] S.C.C.A. No. 454,</span></em> on the other. Arguably, <em>Drady</em> and <em>Attis</em> require a more direct
    connection between a plaintiff and the regulator before the latter can be said
    to owe a duty of care to the former than does <i>Sauer</i>.</p>
  <p class=AParaNumbering>[4]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Mr.
    Bill Sauer, the representative plaintiff in <em>Sauer</em><em><span
style='font-style:normal'>,</span></em><em> </em>was granted leave to intervene
    in this proceeding.</p>
  <p class=MHeading12><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>II<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>&nbsp;</p>
  <h1>THE UNDERLYING CLASS ACTION PROCEEDING</h1>
  <h5>(a)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Nature of the Claim </h5>
  <p class=AParaNumbering>[5]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
    plaintiff, Ms. Taylor, brings the claim as representative of the class of
    persons resident in Canada (except British Columbia and Québec) who have
    suffered damages as a result of the implantation of temporomandibular joint implants
    after 1968. The implants were manufactured by an American company, Vitek Inc.,
    and sold in Canada. Although Vitek manufactured different models of the
    implants, there is no need to distinguish among the various models for present
    purposes. I will refer to the implants as “Vitek TMJ implants”, “TMJ implants”
    or simply as the “implants”. </p>
  <p class=AParaNumbering>[6]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>On
    April 22, 1988, a Vitek TMJ implant was inserted into Ms. Taylor’s right
    temporomandibular joint. She alleges that the insertion of that device
    “resulted in catastrophic and irreversible adverse biomedical consequences,
    resulting in permanent total disability and loss of enjoyment of life.” </p>
  <p class=AParaNumbering>[7]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In
    her claim brought against the Attorney General of Canada (“AG Canada”), Ms.
    Taylor alleges that the government of Canada, and specifically “Health Canada”,<a
href="#_ftn1" name="_ftnref1" title=""><span class=MsoFootnoteReference><span
class=MsoFootnoteReference><span style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[1]</span></span></span></a> was negligent in the exercise of its responsibilities under the <em>Food and
    Drugs Act, </em><em><span style='font-style:normal'>R.S.C. 1985</span></em>, c.
    F-27 (the “<em><span style='font-style:normal'>Act</span></em>”), and the regulations
    proclaimed under the Act. She alleges that Health Canada owed a duty of care to
    protect her and other class members from unsafe medical devices and that it
    negligently failed to perform that duty in relation to the Vitek TMJ implants. </p>
  <p class=AParaNumbering>[8]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In
    broad terms, the Fresh Statement of Claim alleges a failure to prevent the
    importation and sale of the implants, a failure to adequately monitor and
    regulate the sale of the implants, a failure to warn doctors, dentists and
    consumers of the known dangers associated with the implants, and a failure to
    remediate the harm caused to persons who received the implants. In addition, the
    claim alleges that Health Canada wrongly indicated that a notice of compliance
    had been issued for the implants when in fact none had been issued. Ms. Taylor
    alleges that this was a misrepresentation as to the safety of the implants.</p>
  <p class=AParaNumbering>[9]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Many
    of the particulars of the alleged negligence are set out in para. 165 of the Fresh
    Statement of Claim. The allegations include the following:</p>
  <p class=MsoListBullet2CxSpFirst style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada failed to prevent the importation of the implants
    into Canada from 1983 forward;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada failed to prevent the sale of the implants when it
    learned that they had been imported into Canada;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada failed to properly monitor and regulate the sale of
    the implants in Canada;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada failed to stop further sales of the implants when
    it determined that the manufacturer and distributor were not in compliance with
    the applicable regulations;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada erroneously and publicly declared that a notice of
    compliance had been issued with respect to the implants when in fact none had
    been issued;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada failed to take appropriate steps when it realized
    that it had wrongly and publicly declared that a notice of compliance had been
    issued;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada failed to stop further sales of the implants when
    it became aware of serious health problems associated with the implants in the
    United States;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada ignored warnings from its own “senior scientist”
    that the implants posed an “extreme hazard”;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Health Canada failed to provide doctors, dentists and consumers
    with effective and timely notice of the problems associated with the implants;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>after Health Canada became aware of the dangers associated with
    the implants, it failed to warn those who had received implants of those
    dangers; and</p>
  <p class=MsoListBullet2CxSpLast style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>when Health Canada learned of the dangers associated with the
    implants, it failed to take appropriate steps to mitigate any harm that had
    been caused to persons who had received the implants.</p>
  <h5 style='page-break-after:avoid'>(b)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Procedural History</h5>
  <p class=AParaNumbering style='page-break-after:
avoid'>[10]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>This
    action has a long history. It was commenced in December 1999 and is still at
    the pleadings stage. Ms. Taylor has been one of the representative plaintiffs
    since February 2003 and the only representative plaintiff since 2006. She successfully
    moved to certify the action under the <em>Class Proceedings Act, 1992</em>,
    S.O. 1992, c. 6, in 2007: see <em>Taylor v. Canada (Minister of Health)</em> (2007), 285 D.L.R. (4th) 296 (Ont. S.C.). </p>
  <p class=AParaNumbering>[11]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>On the original certification
    motion, the motion judge, in holding that the statement of claim disclosed a
    reasonable cause of action in negligence, said, at paras. 39-40:</p>
  <p class=CQuote>... In these circumstances, <u>I believe it would be open to a
    court to find that Health Canada’s course of conduct – including the dissemination
    of misinformation in its database – increased the risk to the health of the
    plaintiff and other potential recipients of the implants and gave rise to a
    relationship of proximity with them.</u> </p>
  <p class=CQuote>... On the basis of the pleading alone, I do not consider it to
    be plain and obvious that Ms. Taylor has no chance of success in establishing
    that a relationship of proximity – as required to establish a private law duty
    of care – existed in connection with operational acts of Health Canada. ... [Emphasis
    added.]</p>
  <p class=AParaNumbering>[12]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The motion judge
    relied in part on <em>Sauer</em>.</p>
  <p class=AParaNumbering>[13]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>AG Canada applied for
    leave to appeal to the Divisional Court from the certification order. Leave was
    refused: see <em>Taylor v. Canada (AG)</em> (2007), 289 D.L.R. (4th) 567. </p>
  <p class=AParaNumbering>[14]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Shortly after leave to
    appeal was refused, this court released judgments in <em>Drady </em>and <em>Attis</em>. <em>Drady</em> was an intended class action brought on behalf of individuals
    who had also received temporomandibular joint implants. In fact, Mr. <em><span
style='font-style:normal'>Drady</span></em> had been a co-representative
    plaintiff with Ms. Taylor at one time in this action. Unlike Ms. Taylor, however,
    Mr. <em><span style='font-style:normal'>Drady</span></em> did not identify the
    manufacturer of his implant. <em>Attis</em> was an intended class action
    brought on behalf of women who had received breast implants. </p>
  <p class=AParaNumbering>[15]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In <em>Drady</em> and <em>Attis</em>,
    this court held that the challenged pleadings did not allege a reasonable cause
    of action in that they did not contain facts capable of establishing that the
    regulator owed a private law duty of care to the recipients of the implants. In <em>Drady</em>, this court expressly rejected part of the analysis underlying
    the motion judge’s original decision to certify this action: see <em>Drady</em>,
    at paras. 34 and 44-50.</p>
  <p class=AParaNumbering>[16]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Relying on <em>Drady</em> and <em>Attis</em>, AG Canada returned to the motion judge asking him to
    reconsider his earlier decision and decertify this action. AG Canada argued
    that read in the light of the analysis in <em>Drady</em> and <em>Attis</em>, Ms.
    Taylor’s claim did not allege facts that could support a finding that the
    regulator owed a private law duty of care to Ms. Taylor.</p>
  <p class=AParaNumbering>[17]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In his reasons on the motion
    to decertify, the motion judge expressed considerable difficulty in reconciling <em>Drady</em> and <em>Attis</em> with <em>Sauer</em>. He determined, however,
    that the pleadings in this case could not be distinguished from the pleadings
    in <em>Drady</em><em><span style='font-style:normal'>. Like the </span></em><em>Drady</em><em><span
style='font-style:normal'> pleadings, these did not allege a relationship of
    sufficient</span></em> proximity. The motion judge further held, however, that
    Ms. Taylor should be given an opportunity to amend her pleadings: see <em>Taylor
    v. Canada (Ministry of Health)</em>, 2010 ONSC 4799, 81 C.C.L.T. (3d) 106, at
    paras. 21-26, 48-49 and 76.</p>
  <p class=AParaNumbering>[18]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Ms. Taylor produced a Fresh
    Statement of Claim in which she alleged, among other things, various public
    representations made by Health Canada to the effect that its regulatory scheme
    was designed to protect individual consumers who used medical devices like the
    Vitek implants by the enforcement of that scheme and the exercise of the
    investigatory powers available under that scheme. The motion judge held, at
    para. 73, that these representations, considered in the context of the rest of
    the claim, and read generously, were sufficient to allow the claim to survive
    the pleadings stage:</p>
  <p class=CQuote>I believe I should accept the amended pleadings on the ground
    that – when it is read generously – it is not plain and obvious that a finding
    of proximity could not be made at trial if the factual allegations pleaded are
    proven. At the very least, in view of the need for clarification of the
    requirements for an effective public assumption of a private law duty of care,
    I consider that this is a case in which it should be held that the particular
    issue on which proximity turns is not fully settled in the jurisprudence within
    the meaning of the decisions cited in paragraph 47 above. In such cases it has
    been held that the issue in dispute is best left to be dealt with at trial on
    the basis of a full evidentiary record.</p>
  <p class=AParaNumbering>[19]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>AG Canada filed an
    application for leave to appeal from that decision to the Divisional Court. The
    parties ultimately agreed, however, that in the very unusual circumstances of
    this case, a motion should be brought to this court to state a special case
    under Rule 22.03, thereby bringing the dispute directly to this court.</p>
  <p class=MHeading12><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>III<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>&nbsp;</p>
  <h1>The Legal Context</h1>
  <p class=AParaNumbering>[20]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The special case
    arises out of a class action and a motion to decertify the class action on the
    basis that the statement of claim does not allege a reasonable cause of action
    against AG Canada. That context brings two legal principles to the forefront. </p>
  <p class=AParaNumbering>[21]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>First, the statement
    of claim must disclose that the representative plaintiff, Ms. Taylor, has a reasonable
    cause of action against AG Canada. In the context of a negligence claim, this
    requirement means that the pleadings provide a basis upon which AG Canada could
    be said to owe a private law duty of care to Ms. Taylor. It is not enough that
    on the pleadings some other member or members of the class may have a cause of
    action in negligence against AG Canada: see <em>Hughes v. Sunbeam Corp. (Canada)
    Ltd.</em> (2002), 61 O.R. (3d) 433, at paras. 10-18 (C.A.); <em>Taylor v.
    Canada (Ministry of Health)</em>, 2010 ONSC 4799, at para. 61. </p>
  <p class=AParaNumbering>[22]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Second, the claim can
    only be struck at this stage if, assuming the facts pleaded are true, it is
    plain and obvious that the pleading discloses no reasonable cause of action,
    meaning that the plaintiff has no reasonable prospect of success: see <em>Hunt
    v. Carey Canada Inc.</em>, [1990] 2 S.C.R. 959, at 980; <em>R. v. Imperial
    Tobacco Canada Ltd.</em><em><span style='font-style:normal'>,</span></em> 2011
    S.C.C. 42, [2011] 3 S.C.R. 45, at paras. 17-19; <em>Wellington v. Her Majesty
    the Queen (Ontario)</em> (2011) ONCA 274 at para. 14. Placing the test to be
    applied on a motion to strike a claim in the context of the issue raised here,
    the question becomes – has AG Canada demonstrated that Ms. Taylor does not have
    a reasonable prospect, on the facts as alleged, of establishing that Health
    Canada owed her and the other members of her class a private law duty of care?  If
    the question gives rise to genuine legal or factual uncertainties, it cannot be
    answered at this stage and the answer must await a trial and a complete record.   </p>
  <p class=MHeading12 style='page-break-after:
avoid'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>IV<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>&nbsp;</p>
  <h1>The Pleadings</h1>
  <p class=AParaNumbering style='page-break-after:
avoid'>[23]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The questions
    posed by the special case require an examination of the substance of the Fresh
    Statement of Claim. That examination is not an easy one. The Fresh Statement of
    Claim is lengthy (61 pages, 268 paragraphs), prolix, and somewhat disorganized.
    I will begin with an outline of the relevant chronology and then turn to the
    parts of the claim that address the representations made by Health Canada and
    the reliance on those representations by Ms. Taylor and other class members.<a
href="#_ftn2" name="_ftnref2" title=""><span class=MsoFootnoteReference><span
class=MsoFootnoteReference><span style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[2]</span></span></span></a> The bracketed references are to paragraph numbers in the Fresh Statement of
    Claim.</p>
  <h6>(a)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Chronology </h6>
  <p class=AParaNumbering>[24]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In January 1983, Vitek
    and its Canadian distributor, Instrumentarium, began advertising Vitek TMJ
    implants in various Canadian and American journals directed at doctors and
    dentists. The advertisements continued over several years (para. 59). </p>
  <p class=AParaNumbering>[25]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Vitek TMJ implants
    were first sold in Canada in March 1983 (para. 80). Health Canada was not made
    aware of those sales by Vitek until 1987 (paras. 79-80). </p>
  <p class=AParaNumbering>[26]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In May 1983, Vitek
    advised Health Canada that it intended to export TMJ implants to Canada. Vitek
    sought confirmation from Health Canada that the importation would be permitted by
    Health Canada (para. 54). A Health Canada official replied that as the devices
    were medical implants, they could be sold in Canada only if Vitek obtained a
    notice of compliance from Health Canada under the regulations (para. 55). Health
    Canada officials reiterated this position on several occasions in 1983 and 1984
    (paras. 60-61, 63-64). No steps were taken to prevent Vitek or its distributor
    from selling the implants in Canada during the period from 1983 to 1985 (para.
    66).</p>
  <p class=AParaNumbering>[27]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In March 1986, an
    official with Health Canada advised the distributor that a notice of compliance
    was not required before the TMJ implants could be sold in Canada. This position
    contradicted the position taken by Health Canada in the three previous years. This
    official was, however, critical of the distributor’s compliance with various
    regulations. No follow-up inspections were made (paras. 71-73).</p>
  <p class=AParaNumbering>[28]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In September 1986,
    surgeons in the United States reported biomechanical failures of Vitek TMJ
    implants (para. 78).</p>
  <p class=AParaNumbering>[29]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In early 1987, Vitek
    delivered submissions to Health Canada in support of the application for a
    notice of compliance in respect of the implants (para. 79). Throughout 1987,
    contrary to its position in March 1986, Health Canada officials corresponded
    with Vitek and its distributor, indicating that further and better information
    was needed before a notice of compliance could be issued. In 1987, Vitek, with
    Health Canada’s knowledge, continued to sell the implants in Canada (paras. 79,
    81-84). In December 1987, a Health Canada official again advised Vitek and its
    distributor that the implants could not be sold in Canada unless Vitek obtained
    a notice of compliance (para. 86).</p>
  <p class=AParaNumbering>[30]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>On April 22, 1988, Ms.
    Taylor underwent surgery at Toronto General Hospital. A Vitek TMJ implant was
    placed in her right temporomandibular joint (para. 175). </p>
  <p class=AParaNumbering>[31]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Throughout 1988, Vitek
    continued to make submissions to Health Canada in support of its efforts to
    obtain a notice of compliance. It also contended that as it had sold Vitek TMJ
    implants in Canada prior to April 1, 1983, those implants were “grandfathered” under
    the regulations and did not require a notice of compliance before they could be
    sold. Health Canada officials continued to request further documentation
    (paras. 94-97, 100).</p>
  <p class=AParaNumbering>[32]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Sometime in 1988,
    Health Canada erroneously indicated in its database that notices of compliance
    had been issued for Vitek TMJ implants (paras. 102-107). In April 1989, a
    Health Canada official, relying on this error, indicated that Vitek was in compliance
    with the regulations and had data establishing the safety of the implants
    (para. 105). In August 1989, in reliance on the error in the database, Health
    Canada circulated Information Letter #765 indicating that notices of compliance
    had been issued for Vitek TMJ implants (para. 106). The error was not
    discovered until 1990. No steps were taken to notify health professionals or
    their patients of the error when it was discovered (para. 107). </p>
  <p class=AParaNumbering>[33]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In July 1988, Vitek
    withdrew TMJ implants from the market. U.S. authorities reported a lack of
    mechanical testing of the implants (para. 103). </p>
  <p class=AParaNumbering>[34]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In March 1990, Vitek
    issued a voluntary safety alert for Vitek TMJ implants (para. 111). In May
    1990, U.S. authorities ordered a recall of Vitek TMJ implants and notified
    Health Canada. In the notification, the American authorities indicated that
    Vitek TMJ implants could fragment and lead to progressive bone degenerative
    change and giant cell reaction. Health Canada took no immediate action (para.
    112). </p>
  <p class=AParaNumbering>[35]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In August 1990, Health
    Canada asked Instrumentarium to voluntarily refrain from distributing certain
    of the implants. In October 1990, Instrumentarium undertook a voluntary recall
    and notified surgeons who had used the implants. Health Canada supervised the
    recall and notification (paras. 117-119). </p>
  <p class=AParaNumbering>[36]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Between December 1990
    and May 1992, U.S. authorities issued a number of safety alerts, recalls,
    public health notices, and import alerts in respect of the TMJ implants (paras.
    119-120, 122, 128-129, 131, 133). Health Canada was advised of these actions
    and specifically, in April 1991, was advised that a recall had been initiated
    after U.S. authorities had determined that the failure of the implants could
    expose patients to a high risk of serious adverse health consequences. Health
    Canada took no direct action in response to these notices (para. 122).</p>
  <p class=AParaNumbering>[37]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Health Canada first
    reacted to the reported failures of the implants and the serious health
    consequences flowing from those failures around June 1991 when it asked the
    Canadian Dental Association to publish in its journal a safety alert that had
    been issued by American regulators six months earlier (para. 124). A similar
    request was made of another professional organization in Canada in October 1991
    (paras. 130, 132).</p>
  <p class=AParaNumbering>[38]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In October 1992,
    Health Canada sent a notice of the December 28, 1990 safety alert issued by the
    American authorities to surgeons whose names appeared on a list provided by the
    American authorities. Health Canada chose not to send this information to all
    doctors and dentists in Canada (paras. 136-138). </p>
  <p class=AParaNumbering>[39]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In August 1994, Health
    Canada, in response to calls it had received, drafted an alert regarding the
    Vitek TMJ implants to be sent only to the 200 professionals who had been
    supplied with the device prior to 1991 (para. 147). In September 1994, more
    than two years after the U.S. authorities had acted, Health Canada issued a
    national import alert forbidding the importation of Vitek TMJ implants into
    Canada (para. 148). </p>
  <p class=AParaNumbering>[40]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In October 1994,
    Health Canada sent certain material to health professionals alerting them to
    the risks associated with the implants and advising of the steps that should be
    taken to monitor patients who had received the implants (para. 151). Also in
    October 1994, Health Canada sent a “Dear TMJ Patient” letter to individuals who
    had received the implants, advising of the risks associated with the implants
    and the need for ongoing medical monitoring. The letter also indicated that
    recipients of the letter would receive updates as they became available. The
    letter provided a hotline number to these individuals who were told that they
    could use the hotline to keep abreast of any new developments (para. 156).</p>
  <p class=AParaNumbering>[41]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In November 1995,
    Health Canada sent an information package to each member of the Quebec
    Association of Oral and Maxillofacial Surgeons. No other provincial association
    received that information (para. 159). </p>
  <p class=AParaNumbering>[42]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Beginning in February
    1996, employees within Health Canada expressed concerns about the adequacy of
    the notification that had been given to patients who had received the implants.
    These concerns were expressed over a number of months. Ultimately, Health
    Canada decided that no further notification to those who had received the
    implants was necessary (paras. 160-164).</p>
  <h6 style='page-break-after:avoid'>(b)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Alleged Representations and Reliance</h6>
  <p class=AParaNumbering style='page-break-after:
avoid'>[43]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>On
    the motion to decertify, the motion judge, at para. 51, focussed on the absence
    of any alleged representations made by Health Canada that came to the attention
    of Ms. Taylor and were relied on by her. The motion judge expressed the concern
    that in the light of <em>Drady</em>, the failure to allege any direct representations
    and reliance could be fatal to the allegation of a private law duty of care
    owed by Health Canada to Ms. Taylor.</p>
  <p class=AParaNumbering>[44]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Ms. Taylor attempted
    to meet the motion judge’s concerns in her proposed amendments. She alleged representations
    made by Health Canada through documents described in the Fresh Statement of
    Claim as Regulatory Impact Assessment Statements (“RIAS”) and representations
    made in documents described as annual Project Area Reviews. The allegations in
    respect of the RIAS are found in paras. 25-30 of the Fresh Statement of Claim. Because
    of their significance on the motion, I will set out paras. 25, 26 and 29 in
    full:</p>
  <p class=CQuote>25. The Regulatory Impact Assessment Statements (“RIAS”) were
    published by Health Canada in the Canada Gazette to provide a contextual public
    explanation for individual amendments to the Medical Device[s] Regulations. <span
class=Underline>As official government publications, the RIAS are <i>prima
    facie</i> representations of Health Canada’s habitual practice to monitor and
    assure the safety of medical devices used by Class Members. These
    representations were intended to be, and were, reasonably relied upon by the
    public, including the representative plaintiff and Class Members.</span> It was
    reasonably foreseeable for the representative plaintiff and Class Members to
    rely upon those representations with respect to the safety of medical devices,
    in general, and the Vitek TMJ implants, specifically, given Health Canada’s
    stated authority to regulate medical devices and the repeated, public nature of
    the assurances.</p>
  <p class=CQuote align=center style='text-align:center'>...</p>
  <p class=CQuote>26. The RIAS contain a number of statements that demonstrate
    that <span class=Underline>Health Canada clearly understood and was
    representing to the Class that the Medical Device[s] Regulations were designed
    to protect individual patients</span> and other specific users of medical
    devices.</p>
  <p class=CQuote>29. The RIAS also clearly stated to the public that the Medical
    Device[s] Regulations were and are actively enforced by Her Majesty. [Emphasis
    added.]</p>
  <p class=AParaNumbering>[45]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Paragraphs 27-28 and
    30 of the Fresh Statement of Claim summarize the content of several RIAS issued
    by Health Canada. All postdate Ms. Taylor’s receipt of the implants by several
    years and none refer to the implants specifically.</p>
  <p class=AParaNumbering>[46]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The allegations in
    respect of the annual Project Area Reviews are found in paras. 36-39 of the
    Fresh Statement of Claim. Paragraph 36 alleges that the Project Area Reviews
    were conducted:</p>
  <p class=CQuote>...to improve the various divisions in the Bureau [a division
    of Health Canada] and to evaluate past and future goals to be executed by
    Health Canada.</p>
  <p class=AParaNumbering>[47]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The Fresh Statement of
    Claim does not expressly allege representations made in the Project Area
    Reviews that were relied on by Ms. Taylor or other class members. Nor is there
    any allegation that the contents of the Project Area Reviews were known to, or
    available to the public. Several references to different Project Area Reviews stress
    the need to protect users from the hazards associated with the clinical use of
    medical devices. Other extracts describe the goal of improving the safety of
    medical devices through adequate standards and testing, thereby minimizing the
    exposure of Canadians to “unsafe and ineffective medical devices”. None of the
    extracts from the Project Area Reviews refers to the implants, although para.
    37 alleges that previous Project Area Reviews addressed generically the
    problems and risks associated with dental and reconstructive implants. </p>
  <p class=AParaNumbering>[48]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In addition to the
    representations and reliance outlined above, the Fresh Statement of Claim alleged
    that Health Canada knew that dentists, oral surgeons, and their patients
    assumed and understood that medical devices such as the implants had been
    approved by Health Canada for sale and use in Canada (para. 21). The Fresh
    Statement of Claim further claimed that Health Canada represented to Ms. Taylor
    and class members that it exercised responsible, professional oversight of
    medical devices in Canada, and that class members reasonably relied on Health
    Canada’s representations to their detriment (paras. 106, 189-94). Finally, Ms.
    Taylor alleges that due to Health Canada’s inadequate attempts at remediation,
    she and other class members retained the implants when doing so posed a danger
    to their health (para. 209).</p>
  <h6 style='page-break-after:avoid'>(c)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Legislative Scheme</h6>
  <p class=AParaNumbering style='page-break-after:
avoid'>[49]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The
    events described in the Fresh Statement of Claim occurred principally between
    1983 and 1995. During that time period, the Vitek TMJ implant was a “device”
    within the meaning of the <em>Food and Drugs Act</em>, R.S.C. 1970, c. F-27,
    and its successor, the <em>Food and Drugs Act</em><em><span style='font-style:
normal'>, R.S.C. 1985, c. F-27</span></em>. The TMJ implant was also subject to
    regulations made under the <em>Food and Drugs Act</em><em><span
style='font-style:normal'>,</span></em> primarily the <em>Medical Devices
    Regulations</em>, R.R.C 1978, c. 871, as amended by SOR/82-914 (the
    “Regulations”).<a href="#_ftn3" name="_ftnref3" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[3]</span></span></span></a> </p>
  <p class=AParaNumbering>[50]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Section 14 of the
    Regulations prohibited the sale of a device (including implants) unless the
    manufacturer had conducted tests which demonstrated the efficacy of the product.
    Section 15 required that evidence of those tests be supplied to Health Canada
    on request. Section 16 of the Regulations prohibited the importation for sale
    into Canada of devices the sale of which would violate any part of the Act or
    Regulations. Health Canada was given broad powers of inspection by ss. 17
    through 19 of the Regulations.</p>
  <p class=AParaNumbering>[51]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Section 28 of the
    Regulations authorized the Director to request evidence from the manufacturer
    to establish the safety of a particular device. If the evidence was not
    provided by the specified date or if the Director was not satisfied with the
    evidence, then, subject to the submission of further evidence, the sale of the
    device after the specified date was prohibited. </p>
  <p class=AParaNumbering>[52]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Part V of the <em><span
style='font-style:normal'>Regulations</span></em> spoke directly to “new
    devices” and merits further examination.<a href="#_ftn4" name="_ftnref4"
title=""><span class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[4]</span></span></span></a> Under s. 32 of the Regulations, a “new device” was defined in part as:</p>
  <p class=CQuote>...a device listed in the table to this Part that</p>
  <p class=CQuote>(a) has not been sold previously in
    Canada by that manufacturer…</p>
  <p class=AParaNumbering>[53]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The “table” referred
    to in the definition of “new device” included only intra-uterine devices and
    cardiac pacemakers in 1978. The table was amended by SOR/82-914 (October 8,
    1982), to include:</p>
  <p class=CQuote>Any device designed to be implanted into the tissues or body
    cavities of a person for 30 days or more.</p>
  <p class=AParaNumbering>[54]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>After the amendment to
    the table, TMJ implants were a “new device” under Part V of the Regulations
    unless they had been sold in Canada by Vitek prior to the amendment to the
    Table in October 1982.<a href="#_ftn5" name="_ftnref5" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[5]</span></span></span></a> </p>
  <p class=AParaNumbering>[55]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Assuming, as alleged
    by Ms. Taylor, that the implants were a “new device”, s. 33 of the <em><span
style='font-style:normal'>Regulations</span></em> prohibited any manufacturer
    from selling or advertising the implants except in accordance with the
    Regulations. Sections 34 and 35 directed that a manufacturer must obtain a
    notice of compliance from the “Director”, a senior official in Health Canada,
    before selling a “new device”.  </p>
  <p class=AParaNumbering>[56]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In the application for
    a notice of compliance, the manufacturer was required to provide evidence of
    the safety and effectiveness of the device. Section 35 of the Regulations
    outlined some of the specific topics that had to be addressed in the material provided
    by the manufacturer. For example, the manufacturer was required to submit
    evidence of the “quality control program and procedures used during
    manufacturing...”: see s. 35(1)(a)(vii). The manufacturer was also required to submit
    evidence of “the results of all clinical trials to show the effectiveness of the
    device”: see s. 35(b)(i). Section 39 required information referable to
    labelling and packaging. </p>
  <p class=AParaNumbering>[57]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The Director had 60
    days from the receipt of the manufacturer’s material to decide whether to issue
    a notice of compliance. The Director could require further and better
    information from the manufacturer: see ss. 35(2) and 36. </p>
  <p class=AParaNumbering>[58]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Section 36 set out the
    test the Director was to apply in deciding whether to issue a notice of
    compliance:</p>
  <p class=CQuote>36. Within 60 days after the latest date of the receipt by the
    Director of evidence, materials or information submitted by a manufacturer
    under section 35,</p>
  <p class=CQuote>(a) where the Director is satisfied that the <span
class=Underline>manufacturer has provided substantial evidence</span> that</p>
  <p class=CQuote>  (i) the conditions of production and quality control are
    suitable for controlling the quality, stability, safety and performance of the
    new device,</p>
  <p class=CQuote>  (ii) the new device can be used for the purpose and under the
    conditions of use recommended by the manufacturer without undue risk to humans,</p>
  <p class=CQuote>  (iii) the new device is clinically effective for the purpose
    and under the conditions of use recommended by the manufacturer or that
    sufficient animal studies have been carried out to establish a probability of
    effectiveness in humans, and</p>
  <p class=CQuote>  (iv) the drafts of all labels, package inserts, product
    brochures and file cards to be used in connection with the device are adequate,</p>
  <p class=CQuote>the Director shall issue to the manufacturer a notice of
    compliance... [Emphasis added.]</p>
  <p class=AParaNumbering>[59]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The Regulations were
    clear that the Director “shall” issue the notice of compliance if he or she is
    satisfied that the manufacturer has provided “substantial evidence” to support
    the criteria set out in s. 36(a). The Director did not make a determination as
    to the ultimate efficacy of the device, the risks associated with the use of
    the device, or the adequacy of any warnings or instructions provided with the
    device.</p>
  <p class=AParaNumbering>[60]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Section 40 of the
    Regulations allowed the Director to suspend or cancel a notice of compliance
    where “it is necessary to do so in order to safeguard public health or promote
    public safety”. The power to suspend or cancel was discretionary. If a notice
    of compliance were suspended, the medical device could not be sold in Canada
    while the suspension was in effect. Under s. 41, the Director could also
    require a manufacturer who has received a notice of compliance in respect of a
    medical device to file additional material referable to the criteria set out in
    s. 33. The Director could require the further information to satisfy him or
    herself that the requirements for issuing the notice of compliance continue to
    exist.  </p>
  <p class=AParaNumbering>[61]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>This court examined
    the relevant provisions of the <em>Food and Drugs Act</em> and the regulations
    made under that <em><span style='font-style:normal'>Act</span></em> referable
    to medical devices in <em>Attis</em><em><span style='font-style:normal'>,</span></em> at paras. 54-58, and <em>Drady</em><em><span style='font-style:normal'>,</span></em> at paras. 15-19. As explained in <em>Attis</em>, at para. 56, the <em>Food and
    Drugs Act</em> placed obligations as to the safety of medical devices on the
    manufacturer and distributor of those devices. Further, as observed in <em>Drady</em>,
    at para. 19, nothing in the <em><span style='font-style:normal'>Act</span></em> or Regulations placed any obligation on Health Canada to issue warnings
    relating to medical devices. </p>
  <p class=AParaNumbering>[62]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The legislative
    landscape was described by Lang J.A. in <em>Attis</em>, at para. 57:</p>
  <p class=CQuote>A reading of the legislative history of the regulations
    discloses that there was no obligation on Health Canada to undertake safety and
    efficacy testing, or to engage in any other compliance or enforcement
    mechanism. The regulations simply authorized Health Canada to enforce the
    various aspects of the compliance requirements if it chose to do so. <span
class=Underline>Thus, Health Canada was akin to an overseer or watchdog, able
    to employ discretionary, but not mandatory, enforcement of the legislative
    scheme.</span><span class=Underline><span style='text-decoration:none'> [Emphasis
    added.]</span></span></p>
  <p class=MHeading12 style='page-break-after:
avoid'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>V<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>&nbsp;</p>
  <h1>THE FIRST QUESTION</h1>
  <p class=AParaNumbering style='page-break-after:
avoid'>[63]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>For
    convenience, I repeat the first question posed by the special case:</p>
  <p class=CQuote>What are the requirements in a statement of claim to establish
    sufficient proximity between the plaintiff and the defendant in a claim brought
    against a governmental body<a href="#_ftn6" name="_ftnref6" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[6]</span></span></span></a> for regulatory negligence?</p>
  <p class=AParaNumbering>[64]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>This question engages
    the broader consideration of when it will be said that a government regulator
    owes a private law duty of care to those affected by the actions of the
    regulator. None of the parties to this appeal suggests that this question
    admits of a definitive, exhaustive answer. The jurisprudence in the last
    decade, particularly several cases from the Supreme Court of Canada, does,
    however, delineate the approach to be taken when faced with a claim in
    negligence brought against a government regulator. </p>
  <p class=MsoHeading7>(a)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Duty of Care Inquiry</p>
  <p class=AParaNumbering>[65]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Liability in
    negligence is predicated on the existence of a duty owed by the defendant to
    the plaintiff to take reasonable care in the circumstances. Proximity is essential
    to, but alone does not establish a duty of care. Proximity is one aspect of the
    broader duty of care inquiry: see <em>Odhavji Estate v. Woodhouse</em>, 2003
    SCC 69, [2003] 2 S.C.R. 263, at paras. 45-46. </p>
  <p class=AParaNumbering>[66]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The proximity
    requirement cannot be reduced to a list of factors or circumstances which, if
    they exist, will always create a relationship of proximity between a plaintiff
    and a defendant. Proximity is a concept, not a test: see <em>Canadian National
    Railway Co. v. Norsk Pacific Steamship Co.</em>, [1992] 1 S.C.R. 1021, at 1151.
    The concept of proximity describes a relationship between a plaintiff and a
    defendant that is sufficiently close and direct to render it fair and
    reasonable to require that the defendant, in the conduct of its affairs, be
    mindful of the plaintiff’s legitimate interests: see <em>Cooper v. Hobart</em>,
    2001 SCC 79, [2001] 3 S.C.R. 537, at paras. 32-36. </p>
  <p class=AParaNumbering>[67]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Reasonable
    foreseeability of harm, arguably the basis upon which at least a <em>prima
    facie</em> duty of care was imposed pre-<em>Cooper</em><em><span
style='font-style:normal'>,</span></em><a href="#_ftn7" name="_ftnref7" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[7]</span></span></span></a> does not necessarily establish a relationship of proximity: see <em>Hill v.
    Hamilton-Wentworth Regional Police Services Board</em>, 2007 SCC 41, [2007] 3
    S.C.R. 129, at para. 23; <em>Childs v. Desormeaux</em>, 2006 SCC 18, [2006] 1
    S.C.R. 643, at para. 31. As explained in <em>R. v. Imperial Tobacco Canada
    Limited</em><em><span style='font-style:normal'>,</span></em> 2011 SCC 42,
    [2011] 3 S.C.R. 45, at para. 41:</p>
  <p class=CQuote>Proximity and foreseeability are two aspects of one inquiry –
    the inquiry into whether the facts disclose a relationship that gives rise to a <em>prima facie</em> duty of care at common law. Foreseeability is the
    touchstone of negligence law. However, not every foreseeable outcome will
    attract a commensurate duty of care. Foreseeability must be grounded in a relationship
    of sufficient closeness or proximity, to make it just and reasonable to impose
    an obligation on one party to take reasonable care not to injure the other.</p>
  <p class=AParaNumbering>[68]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>If reasonable
    foreseeability is established, the court will look to the other factors that
    inform the nature of the relationship between the plaintiff and the defendant to
    determine whether that relationship is one of sufficient proximity. <em>Cooper</em> describes the factors as “diverse” and case-specific: see para. 35. In <em>Hill</em>,
    at para. 29, the court provides this insight:</p>
  <p class=CQuote>The most basic factor upon which the proximity analysis fixes
    is whether there is a relationship between the alleged wrongdoer and the
    victim, usually described by the words “close and direct”. <span
class=Underline>This factor is not concerned with how intimate the plaintiff
    and defendant were or with their physical proximity, so much as with whether
    the <i>actions</i> of the alleged wrongdoer have a close or direct effect on
    the victim, such that the wrongdoer ought to have had the victim in mind as a
    person potentially harmed.</span> A sufficiently close and direct connection
    between the actions of the wrongdoer and the victim may exist where there is a
    personal relationship between the alleged wrongdoer and victim. However, it may
    also exist where there is no personal relationship between the victim and
    wrongdoer. [Italic emphasis in original. Underline emphasis added.]</p>
  <p class=AParaNumbering>[69]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>While the authorities are
    careful to deny that any one factor or combination of factors is necessary to
    establish proximity, certain factors will routinely take a central role in the
    proximity analysis. These include any representations made by the defendant,
    especially if made directly to the plaintiff, reliance by the plaintiff on the
    defendant’s representations, the nature of the plaintiff’s property or other
    interest engaged, the specific nature of any direct contact between the
    plaintiff and the defendant, and the nature of the overall relationship
    existing between the plaintiff and the defendant: see <em>Cooper</em>, at
    paras. 34-35; <em>Hill</em>, at paras. 29-30. </p>
  <p class=MsoHeading7>(b)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Format of the Duty of Care Inquiry</p>
  <p class=AParaNumbering>[70]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The Supreme Court of
    Canada jurisprudence has developed and refined a template to be applied in
    deciding whether any given relationship between a plaintiff and a defendant gives
    rise to a private law duty of care. Much of that jurisprudence involves negligence
    allegations brought by individuals against governmental authorities.</p>
  <p class=AParaNumbering>[71]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Under the approach developed
    in the Supreme Court jurisprudence, there are two stages to the duty of care inquiry.
    The first stage is directed at the specifics of the individual case and decides
    whether the relationship between the plaintiff and the defendant justifies the
    imposition of a <em>prima</em> <em>facie</em> duty of care. The second stage of
    the inquiry, reached only if a <em>prima facie</em> duty of care is found,
    looks beyond the specifics of the case to broader residual policy concerns and
    asks whether those concerns justify the negation of the <em>prima</em> <em>facie</em><em><span
style='font-style:normal'> duty of care</span></em>.  </p>
  <p class=AParaNumbering>[72]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The two-stage approach
    is clearly summarized in <em>Edwards v. Law Society of Upper Canada</em>, 2001
    SCC 80, [2001] 3 S.C.R. 562, at paras. 9-10: </p>
  <p class=CQuote>At the first stage of the <em>Anns</em><a href="#_ftn8"
name="_ftnref8" title=""><span class=MsoFootnoteReference><i><span
class=MsoFootnoteReference><b><span style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[8]</span></b></span></i></span></a> test, the question is whether the circumstances disclose reasonably foreseeable
    harm and proximity sufficient to establish a <em>prima facie</em> duty of care.
    The focus at this stage is on factors arising from the relationship between the
    plaintiff and the defendant, including broad considerations of policy. The
    starting point for this analysis is to determine whether there are analogous
    categories of cases in which proximity has previously been recognized. If no
    such cases exist, the question then becomes whether a new duty of care should
    be recognized in the circumstances. Mere foreseeability is not enough to
    establish a <em>prima facie</em> duty of care. The plaintiff must also show
    proximity – that the defendant was in a close and direct relationship to him or
    her such that it is just to impose a duty of care in the circumstances. ...</p>
  <p class=CQuote>If the plaintiff is successful at the first stage of <i>Anns</i> such that a <em>prima facie</em> duty of care has been established (despite the
    fact that the proposed duty does not fall within an already recognized category
    of recovery), the second stage of the <i>Anns</i> test must be addressed. That question
    is whether there exist residual policy considerations which justify denying
    liability. Residual policy considerations include, among other things, the
    effect of recognizing that duty of care on other legal obligations, its impact
    on the legal system and, in a less precise but important consideration, the
    effect of imposing liability on society in general.</p>
  <p class=AParaNumbering>[73]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The questions posed in
    this special case focus exclusively on the first stage of the duty of care
    inquiry described in <em>Edwards</em>.  At the first stage of the inquiry, the
    court begins by asking whether the claim advanced describes a relationship that
    is the same as or analogous to a relationship that courts have previously
    recognized as giving rise to a <em>prima facie</em> duty of care. If the
    relationship fits within that description, the court, in the interest of
    consistency and efficiency, will assume a <em>prima facie</em> duty of care and
    move directly to the second stage of the duty of care inquiry. Similarly, if
    courts have previously determined that the same or an analogous relationship
    does not create a <em>prima facie</em> duty of care, the court will, generally
    speaking, not repeat the analysis, but will find no duty of care based on the
    prior authority: see <em>Childs</em>, at para. 15; <em>Imperial Tobacco</em>,
    at para. 37; <em>Heaslip Estate v. Ontario</em><em><span style='font-style:
normal'>,</span></em> 2009 ONCA 594, 96 O.R. (3d) 401, at para. 21; <em>Wellington
    v. Ontario</em><em><span style='font-style:normal'>,</span></em> 2011 ONCA 274,
    105 O.R. (3d) 81, at para. 16.</p>
  <p class=AParaNumbering>[74]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In deciding whether an
    allegation fits within an established category or is analogous to an
    established category, the court must guard against treating the allegations at
    an abstract or generic level. For example, courts have long recognized a tort
    of negligent misrepresentation. It does not follow, however, that every
    allegation of negligent misrepresentation fits within that established
    category. As explained in <em>Imperial Tobacco</em>, at para. 37:</p>
  <p class=CQuote>The first question is whether the facts as pleaded bring
    Canada’s relationships with consumers and the tobacco companies within a
    settled category that gives rise to a duty of care. If they do, a <em>prima
    facie</em> duty of care will be established [citation omitted]. However, it is
    important to note that liability for negligent misrepresentation depends on the
    nature of the relationship between the plaintiff and the defendant... <span
class=Underline>The question is not whether negligent misrepresentation is a
    recognized tort, but whether there is a reasonable prospect that the
    relationship alleged in the pleadings will give rise to liability for negligent
    misrepresentation.</span> [Emphasis added.]</p>
  <p class=MsoHeading7>(c)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The Duty of Care Inquiry and Regulatory Negligence</p>
  <p class=AParaNumbering>[75]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>If the claim does not
    fall within an established or an analogous category, but the harm alleged was reasonably
    foreseeable, proximity becomes the focus of the first stage of the two-stage duty
    of care inquiry. Where the claim is advanced against a regulator, the proximity
    inquiry will focus initially on the applicable legislative scheme and secondly,
    on the interactions, if any, between the regulator or governmental authority and
    the putative plaintiff: see <em>Imperial Tobacco</em>, at paras. 43-45. </p>
  <p class=AParaNumbering>[76]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The legislative scheme
    looms large in the proximity inquiry for two reasons. First, the question of
    whether a regulator should owe a private law duty of care to those individuals
    affected by its actions is largely a policy decision that falls squarely within
    the legislative bailiwick. The legislature announces that policy decision
    through the terms of its legislation. Second, even where the legislation is not
    determinative and the court must look to the interaction between the regulator
    and the plaintiff, the terms of the legislation describing the powers and
    duties of the regulator may to some extent shape the relationship between the
    regulator and the regulated. That relationship will be relevant in deciding
    whether the specific interactions between the regulator and the plaintiff are
    sufficient to create the degree of proximity required to establish a <em>prima
    facie</em> duty of care. </p>
  <p class=AParaNumbering>[77]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The legislative scheme
    must be examined at the outset of the duty of care inquiry. If that scheme
    expressly or by implication forecloses or imposes a private law duty of care,
    the duty of care inquiry need go no further. It is not for the court to
    contradict the terms of the legislative scheme. </p>
  <p class=AParaNumbering>[78]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Legislative schemes
    under which regulators operate almost inevitably impose public duties on those
    regulators. Plaintiffs have, generally speaking, had little success in demonstrating
    that those schemes impose a private law duty of care. To the contrary, courts
    have been more inclined to find that legislative schemes by implication
    preclude a private law duty of care to individuals affected by those schemes. Statutory
    schemes that provide immunity to the regulator, create remedies to injured parties
    other than tort remedies, or impose duties on the regulator that conflict with
    a private law duty of care to an individual have all been held to compel the
    conclusion that the legislative scheme implicitly forecloses a finding that the
    regulator owes a private law duty of care to an individual: see <em>Cooper</em>,
    at paras. 43-44; <em>Edwards</em>, at paras. 16-17; <em>Alberta v. Elder
    Advocates of Alberta Society</em>, 2011 SCC 24, [2011] 2 S.C.R. 261, at para.
    69; <i>Syl Apps Secure Treatment Centre v. B.D.</i>, 2007 SCC 38, [2007] 3
    S.C.R. 83, at paras. 49-50, 59-63; <em>Eliopoulos v. Ontario (Minister of
    Health and Long-Term Care)</em> (2006), 82 O.R. (3d) 321 (C.A), at paras. 14-20.  </p>
  <p class=AParaNumbering>[79]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Where the legislation
    is not determinative one way or the other, the courts explore the specific
    circumstances of the interactions between the regulator and the plaintiff in
    the context of the legislative scheme to decide whether a sufficiently “close
    and direct” relationship exists to justify the imposition of a <em>prima facie</em> duty of care: see <em>Imperial Tobacco</em><em><span style='font-style:normal'>,
    at para. 50; </span></em><em>Hill</em><em><span style='font-style:normal'>, at
    paras. 26-45;</span></em> <em>Fullowka v. Pinkerton’s of Canada Ltd.</em>, 2010
    SCC 5, [2010] 1 S.C.R. 132, at paras. 37-55; <em>Heaslip</em><em><span
style='font-style:normal'>, at paras. 15-31</span></em>. </p>
  <p class=AParaNumbering>[80]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Findings of proximity
    based on the interactions between the regulator and the plaintiff are
    necessarily fact-specific. The jurisprudence does, however, suggest there are
    two important factual features in those cases where the court has found a <em>prima
    facie</em> duty of care. First, the facts demonstrate a relationship and
    connection between the regulator and the individual that is distinct from and
    more direct than the relationship between the regulator and that part of the
    public affected by the regulator’s work. For example, in <em>Hill</em>, at
    para. 33, the court found that the police owed the plaintiff a duty of care in
    conducting their investigation because they had targeted the plaintiff in that
    criminal investigation. By targeting the plaintiff, the police created a
    relationship with the plaintiff that was much more direct than the relationship
    between the police and other members of the public who might also be affected
    by the exercise of police powers. </p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[81]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em>Fullowka</em><em><span style='font-style:normal'> is
    another example of a finding of a duty of care premised on the interaction between
    the plaintiff and the regulator. In </span></em><em>Fullowka</em><em><span
style='font-style:normal'>, at paras. 44 and 55, the court stressed that the
    mine in which the explosion at issue had occurred had been inspected many times
    by the regulator. The regulator was aware of the dangers posed to the miners by
    the strike-related violence and the ineffectiveness of the measures that had
    been taken to prevent that violence. Cromwell J., writing for the court,
    observed, at para. 54:</span></em></p>
  <p class=CQuote><em><span style='font-style:normal'>… [The regulators] had a
    clear and well substantiated belief that the mine was unsafe. … The legislative
    scheme is about safety in mines, it exists to protect miners from acts of
    others and there were clearly identified and well documented findings that the
    miners were subject to unsafe working conditions.</span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[82]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>The specific facts relating
    to the particular mine and the well known safety problems presented at that
    mine were sufficient to create a direct relationship between the regulator responsible
    for the safety of the mine and the miners who worked there. Those actions effectively
    distinguished the relationship between the regulators and the workers in the
    specific mine from the relationship between the regulator and miners in general.</span></em></p>
  <p class=AParaNumbering>[83]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span><em>Heaslip</em><em><span
style='font-style:normal'> provides one of the best examples of the kind of
    interaction </span></em>between a regulator and an individual that will create
    a <em>prima facie</em> duty of care where the operative legislative scheme
    imposes only public duties, but does not foreclose the existence of a private
    law duty that is not inconsistent with the public duties. </p>
  <p class=AParaNumbering>[84]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>In <em>Heaslip</em>,
    the plaintiffs alleged that the government agency responsible for providing air
    ambulance services had negligently failed to follow its own policies when it
    did not give their son’s medical needs priority over the needs of a less
    severely injured person.  The plaintiffs alleged that their son died as a
    result of the regulator’s decision to give priority to the less seriously
    injured individual. </p>
  <p class=AParaNumbering>[85]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>Sharpe J.A.
    acknowledged that the duties found in the relevant legislation were public
    duties that did not give rise to a duty of care as between the plaintiff and
    the regulator. Nor, however, did they foreclose the existence of that duty. Sharpe
    J.A. went on to examine the interaction between the regulator and the
    plaintiff. On the allegations, the regulator had undertaken to provide a
    specific medical service to the plaintiff’s son. The regulator was aware that
    the plaintiff’s son was in need of that service and dependent upon the
    regulator to provide that service. According to the regulator’s policies, the
    plaintiff’s son should have received that service in priority to the person to
    whom the service was provided. </p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[86]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em>In holding that the allegations in the claim gave rise to <em><span
style='font-style:normal'>a </span></em><em>prima facie</em><em><span
style='font-style:normal'> duty of care, Sharpe J.A. said, at paras. 19-20:</span></em></p>
  <p class=CQuote>This case is distinguishable from cases like <em>Cooper</em> and <em>Attis</em>. In those cases, the plaintiffs suffered harm at the hands
    of a party involved in an activity subject to regulatory authority and then
    alleged negligence on the part of the governmental authority charged with the
    duty of regulating the activity that gave rise to the plaintiff’s loss. <em>Cooper</em> and <em>Attis</em> hold that such plaintiffs have no direct relationship with
    the governmental authority and can assert no higher claim to a duty of care
    than any other member of the public. </p>
  <p class=CQuote>The claim asserted here does not rest solely on the statute
    conferring regulatory powers, as in <em>Cooper</em> and <em>Attis</em>, <span
class=Underline>but is focused instead on the specific interaction that took place
    between Patrick Heaslip and Ontario when the request for an air ambulance was
    made. In this case, the relationship between Patrick Heaslip and the
    governmental authority is direct, rather than being mediated by a party subject
    to the regulatory control of the governmental authority.</span><span
class=Underline><span style='text-decoration:none'> [Emphasis added.]</span></span></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[87]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>In holding that there
    was sufficient proximity, </span></em><em>Heaslip</em> draws a distinction
    between (i) a situation in which the actions of the regulator directly impact
    on the individual plaintiff and cause harm to that plaintiff, and (ii)
    situations in which the harm to the plaintiff is caused by the actions of a
    third party and the plaintiff’s claim is that the regulator should have acted
    to prevent the actions of the third party. Not surprisingly, a finding of
    proximity will be more readily made in cases where the actions of the regulator
    directly impact on the plaintiff and cause the physical harm giving rise to the
    claim: see <em>Childs</em>, at para. 31; see also <em>Gorringe v. Calderdale
    Metropolitan Borough Council</em><em><span style='font-style:normal'>,</span></em> [2004] UKHL 15, [2004] 1 W.L.R. 1057, per Lord Hoffman, at para. 38.</p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[88]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>The second feature of
    those cases in which the courts have found that the interactions between the plaintiff
    and the regulator created a </span></em><em>prima facie</em><em><span
style='font-style:normal'> duty of care arises out of the nature of the duty actually
    imposed by the legislative scheme. While the statutory duties are found to be public
    duties and not, therefore, themselves the basis for any private law duty of
    care, those public duties have been found to be consistent with the existence
    of a private law duty of care owed to an individual plaintiff. Thus, in </span></em><em>Hill</em><em><span
style='font-style:normal'>, the Chief Justice found that the recognition of a
    private law duty of care to an individual suspect based on the interaction between
    that suspect and the police promoted the broader public interest in the effective
    and fair police investigation of criminal activity: see paras. 36-41. </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[89]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em> <em>Imperial Tobacco</em><em><span style='font-style:normal'> is instructive in that it presents both an example of an interaction between a
    regulator and the regulated that was sufficient to establish a </span></em><em>prima
    facie</em><em><span style='font-style:normal'> private law duty of care and an
    example of an interaction that was insufficient.</span></em><em><span
style='font-style:normal'> </span></em><em><span style='font-style:normal'>There
    were two different claims made against the regulator, Health Canada, in </span></em><em>Imperial
    Tobacco</em><em><span style='font-style:normal'>. Cigarette manufacturers
    argued that Health Canada owed a private law duty of care to consumers of
    cigarettes and a discrete private law duty of care to the manufacturers. They
    alleged that Health Canada had breached both duties by making negligent
    representations concerning the relative safety of low-tar cigarettes. </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[90]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>In examining the
    relationship between the regulator and consumers, the court looked first at the
    legislative scheme and found that it imposed only general duties to the public:
    see paras. 49-50. The court also held, however, that the legislation did not
    preclude the existence of a private law duty of care if the interactions
    between the regulators and a consumer of the product justified the imposition
    of such a duty. The court, however, found no specific interactions between the
    regulators and consumers of cigarettes. The court rejected, at para. 49, the
    contention that the regulator’s assertions to the general smoking public that low-tar
    cigarettes were less hazardous could create a relationship of proximity between
    the regulator and consumers of low-tar cigarettes. </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[91]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>The court next addressed,
    at para. 51 and following, the relationship between the regulator and the
    tobacco companies. Once again, the court found no private law duty of care arising
    from the relevant legislative scheme. However, the court held that the
    allegations in the claim were capable of establishing a direct relationship between
    the regulator and the tobacco manufacturers. According to the allegations, the regulator
    had gone beyond its regulatory role and had become involved with the
    manufacturers in a wide variety of matters, including advising on the growing
    and advertising of various tobacco products. The court concluded that these
    interactions sufficed to create a relationship of proximity between the
    regulator and the manufacturers justifying a finding of a </span></em><em>prima
    facie</em><em><span style='font-style:normal'> duty of care owed to the
    manufacturers by the regulator.</span></em><a href="#_ftn9" name="_ftnref9"
title=""><span class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[9]</span></span></span></a><em><span
style='font-style:normal'> </span></em></p>
  <p class=MsoHeading7><em><span style='font-style:normal'>(d)<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></em><em>Attis</em><em><span style='font-style:normal'>, </span></em><em>Drady</em><em><span
style='font-style:normal'> and </span></em><em>Sauer</em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[92]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>The approach taken to
    the claims in </span></em><em>Drady</em><em><span style='font-style:normal'> and </span></em><em>Attis</em><em><span style='font-style:normal'> is consistent
    with that described above. In both cases, this court looked first at the
    relevant legislative scheme and found that it imposed no private law duty of
    care: see </span></em><em>Attis</em><em><span style='font-style:normal'>, at
    paras. 53-62; </span></em><em>Drady</em><em><span style='font-style:normal'>,
    at paras. 37-39. The court then turned to the pleadings in each case to
    determine whether the interactions between the regulator and the plaintiff set
    forth in the pleadings created a relationship of proximity such as to justify a
    finding of a </span></em><em>prima facie</em><em><span style='font-style:normal'> duty of care. In </span></em><em>Attis</em><em><span style='font-style:normal'>,
    Lang J.A.’s examination included the following observation, at para. 66:</span></em></p>
  <p class=CQuote><em><span style='font-style:normal'>...once the government has
    direct communication or interaction with the individual in the operation or
    implementation of a policy, a duty of care may arise, particularly where the
    safety of the individual is at risk. If, for example, a government decides to
    issue a warning about a specific danger, in this case medical devices, or to
    make representations about the safety of a product, the government may be
    liable for the manner in which it issues that warning, or the content of those
    representations, especially where the government disseminates the warning or
    representation knowing that the individual consumer will rely on its contents
    and the individual does so.</span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[93]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>In </span></em><em>Attis</em><em><span
style='font-style:normal'>, at paras. 69-70, Lang J.A. went on to conclude that
    the facts as pleaded did not establish an interaction between the regulator and
    the plaintiff such as to create a </span></em><em>prima facie</em><em><span
style='font-style:normal'> duty of care.  She noted the absence of any direct
    contact between the plaintiffs and Health Canada and the absence of any
    allegations of representations made by Health Canada and relied on by the
    plaintiffs. She concluded, at para. 70:</span></em><em><span style='font-style:
normal'> </span></em></p>
  <p class=CQuote><em><span style='font-style:normal'>…</span></em>there was no
    interaction with Health Canada that could have led the appellants to believe
    Health Canada had assumed a private law duty of care for product safety.  Nothing
    in the relationship between the parties would lead an individual to assume a
    government product guarantee. Rather, the appellants’ expectations and reliance
    would have been on their medical advisers, the hospital, the manufacturer and
    the distributer of the device. I would conclude that the pleaded facts in this
    case do not support a finding of proximity through interaction.</p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[94]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>Unlike </span></em><em>Attis</em><em><span
style='font-style:normal'> and </span></em><em>Drady</em><em><span
style='font-style:normal'>, which addressed the proximity requirement in
    detail, </span></em><em>Sauer</em><em><span style='font-style:normal'> considers
    proximity in a single conclusory paragraph (para. 62). In that paragraph, the
    court referred to the regulator’s “many public representations” declaring its
    intention to protect “commercial cattle farmers among others”.</span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[95]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>In my view, a finding of
    proximity based entirely on a regulator’s public acknowledgement of its public
    duties to those affected by its actions, coupled with reliance by those
    affected on the regulator’s public statements, is inconsistent with the Supreme
    Court’s rejection in </span></em><em>Imperial Tobacco</em><em><span
style='font-style:normal'> of the claim that Health Canada owed a private law duty
    of care to consumers of low-tar cigarettes because it had made public
    representations as to the relative safety of those cigarettes</span></em><em><span
style='font-style:normal'>.</span></em><a href="#_ftn10" name="_ftnref10"
title=""><span class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:13.0pt;font-family:"Arial","sans-serif"'>[10]</span></span></span></a><em><span
style='font-style:normal'> </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[96]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>Although public
    representations by a regulator as to its public duties and obligations do not
    establish a relationship of proximity between the regulator and an individual
    plaintiff, they are properly included in the factual matrix to be considered in
    determining whether the interactions between a regulator and a plaintiff are
    sufficiently direct and close to warrant a finding of proximity. </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[97]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>This is not the time or
    place to pass upon the ultimate sufficiency of the pleadings in </span></em><em>Sauer</em><em><span
style='font-style:normal'>. I am satisfied, however, that the detailed analyses
    of proximity in </span></em><em>Attis</em><em><span style='font-style:normal'> and </span></em><em>Drady</em><em><span style='font-style:normal'>,
    particularly in the light of the subsequent judgment in </span></em><em>Imperial
    Tobacco</em><em><span style='font-style:normal'>, are more in line with the
    prevailing jurisprudence. The single conclusory observation in </span></em><em>Sauer</em><em><span
style='font-style:normal'>, standing alone, is not consistent with that
    jurisprudence.</span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[98]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>The jurisprudence
    permits no definitive answer for the first question. As counsel for AG Canada
    put it in his factum, “[t]he requirements for proximity are diverse and depend
    on the facts of each particular case.”</span></em></p>
  <p class=MHeading12><em><span
style='font-style:normal'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>VI<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>&nbsp;</span></em></p>
  <h1>the second question </h1>
  <p class=AParaNumbering>[99]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span>The second question states:</p>
  <p class=CQuote>Does the amended statement of claim in this action satisfy
    those requirements?</p>
  <p class=AParaNumbering>[100]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span> The question is
    answered by applying the template fashioned in the jurisprudence to the
    pleadings in this case. As already indicated, this exercise is complicated by
    the diffuse and disorganized nature of the pleadings. </p>
  <p class=AParaNumbering>[101]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>I begin with the
    statutory regime. As outlined above, <em>Attis</em> and <em>Drady</em><em><span
style='font-style:normal'> dealt with the same legislative scheme that is
    before the </span></em>court in this proceeding. Both cases held that the
    scheme did not expressly or by implication create a private law duty of care. Nor
    did the scheme foreclose the existence of that duty in a particular situation.</p>
  <p class=AParaNumbering>[102]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>Neither party in
    this proceeding suggests that the court should reconsider the analysis of the
    legislative scheme conducted in <em>Attis</em> and <em>Drady</em><em><span
style='font-style:normal'>. I see no reason to rework that ground. The fate </span></em>of
    these pleadings turns on whether they allege a sufficient interaction between
    Health Canada and the plaintiff to warrant a finding of proximity and the
    imposition of a <em>prima facie</em> duty of care.</p>
  <p class=AParaNumbering>[103]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>In considering
    whether allegations of interactions between the plaintiff and the regulator are
    sufficient to survive challenge at the pleadings stage, I bear in mind the
    admonition of the Chief Justice in <em>Imperial Tobacco</em>, at para. 47:</p>
  <p class=CQuote>… <u>where the asserted basis for proximity is grounded in
    specific conduct and interactions, ruling a claim out at the proximity stage
    may be difficult.</u> So long as there is a reasonable prospect that the
    asserted interactions could, if true, result in a finding of sufficient
    proximity, and the statute does not exclude that possibility, the matter must
    be allowed to proceed to trial, subject to any policy considerations that may
    negate the <em>prima facie</em> duty of care at the second stage of the
    analysis. [Emphasis added.]</p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[104]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>Where the relationship
    of proximity is said to arise out of the interaction between a plaintiff and
    the regulator, the question must be – what is there in the factual allegations that
    distinguishes the relationship between this plaintiff and the regulator from
    the relationship that exists between the regulator and all those affected by
    the regulator’s actions? In the amendments to her claim found in the Fresh Statement
    of Claim, Ms. Taylor tries to establish a direct and close relationship with
    the regulator by reference to the regulator’s public statements concerning its general
    powers and practices under the legislative scheme and her reliance on them. For
    example, in para. 25, she refers to the RIAS as representations of Health
    Canada’s “habitual practice to monitor and assure the safety of medical devices
    used by Class Members”. Ms. Taylor further alleged that these broad public representations
    “were intended to be and were, reasonably relied on by the public, including the
    representative plaintiff and Class Members.” </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[105]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>For the reasons set out
    above, a regulator’s public statements acknowledging its public duties and
    obligations and its commitment to the performance of those duties, combined
    with the reliance on those public statements by members of the public affected
    by the performance of those duties, cannot, standing alone, create a
    relationship of proximity between individual plaintiffs and the regulator. In
    my view, to assert that the kind of representations made by Health Canada and
    relied on in the Fresh Statement of Claim can, coupled with reliance on those
    representations, create a relationship of proximity, is in reality to assert
    that the public duties set out in the legislative scheme can become a private
    law duty of care if relied on by an individual member of the public. The
    legislative scheme does not create any private law duty of care. An
    individual’s reliance on public representations that the regulator will do its
    public and statutory duty cannot by itself create one.</span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[106]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>The additional
    allegations concerning representations and reliance inserted into the Fresh Statement
    of Claim do not establish a relationship of proximity between Ms. Taylor and
    Health Canada. However, those allegations must be placed in the context of the
    more specific allegations concerning the implants made in the remainder of the
    Fresh Statement of Claim. </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[107]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>I begin my review of
    those specific allegations with three observations. First, there is no
    allegation of any direct contact between the plaintiff and Health Canada. Second,
    it is not alleged that Health Canada’s actions directly caused the harm to Ms.
    Taylor. Rather, it is alleged that Health Canada failed to properly regulate
    those who caused the harm to Ms. Taylor. These two factors make this case
    different from cases like </span></em><em>Heaslip</em><em><span
style='font-style:normal'> and </span></em><em>Hill</em><em><span
style='font-style:normal'>.</span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[108]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>My third observation,
    however, points in the opposite direction. There is nothing inconsistent with a
    finding of a private law duty of care owed to individuals in a particular
    situation and the existence of the public duties owed by Health Canada under
    the legislation. The private law duty of care claimed by Ms. Taylor can coexist
    with the duties and obligations owed by Health Canada to the public.</span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[109]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>The sustainability of
    Ms. Taylor’s claim at this stage of the proceedings depends primarily on the
    allegations of Health Canada’s misrepresentations as to the status of the Vitek
    implants between 1988 and 1990 and its failure to correct those
    misrepresentations in the following years during which the implants were sold
    into Canada without proper authorization and the evidence of the danger posed
    by those implants continued to mount. Those allegations can be summarized as
    follows:</span></em></p>
  <p class=MsoListBullet2CxSpFirst style='line-height:200%'><em><span
style='font-family:Symbol;font-style:normal'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>no later than 1987,
    Vitek, with Health Canada’s knowledge, was selling implants in Canada without
    the necessary notice of compliance; </span></em></p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Ms. Taylor received one of those Vitek implants in Canada in
    April 1988;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>sometime in 1988, Health Canada wrongly represented in its
    database that it had issued a notice of compliance referable to the Vitek implants; </p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>at various times in 1989, Health Canada, through its officials,
    repeated the misrepresentation concerning the status of the Vitek implants and
    indicated that Vitek had filed data establishing the safety of the implants to Health
    Canada’s satisfaction;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>in 1990 Health Canada discovered that it had wrongly represented
    that the Vitek implants had received a notice of compliance, but it took no
    steps to advise users or potential users of the implants or their health care
    professionals of Health Canada’s misrepresentation;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>to Health Canada’s knowledge, Vitek continued to sell implants in
    Canada between 1988 and 1990, without the requisite notice of compliance;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>beginning in 1990, Health Canada received information from various
    reliable sources reporting significant defects causing the implants to fail and
    resulting in serious health consequences for those who had received the
    implants;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>between 1990 and 1992, Health Canada was advised of various
    safety alerts, recalls, public health notices, and import alerts issued by
    American authorities in relation to the implants; </p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>between 1990 and 1996, Health Canada failed to take any or took
    inadequate steps in response to the information received;</p>
  <p class=MsoListBullet2CxSpMiddle style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>throughout the period, Health Canada represented to consumers
    that it monitored and assured the safety of medical devices; and</p>
  <p class=MsoListBullet2CxSpLast style='line-height:200%'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>Ms. Taylor and other class members relied on this representation.</p>
  <p class=AParaNumbering>[110]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>Reading Ms.
    Taylor’s pleadings generously, they allege that between 1988 and 1990 Health
    Canada repeatedly misrepresented the safety of the implants Ms. Taylor and
    others received by wrongly representing that those implants had received a
    notice of compliance.  The pleadings further allege that when Health Canada became
    aware of its misrepresentation in 1990, it failed to correct that
    misrepresentation despite the knowledge that the implants were being improperly
    imported and sold in Canada and that there was strong and growing evidence that
    the implants were unsafe and caused serious harm to users. These allegations,
    taken in combination, in my view, describe a relationship between Health Canada
    and the users of those implants that is different from the relationship that exists
    between Health Canada and consumers of medical devices at large.  The more
    difficult question is whether the allegations create a sufficiently close
    relationship to give rise to a private law duty of care. </p>
  <p class=AParaNumbering>[111]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>In referring to
    the combined effect of Health Canada’s misrepresentations as to the compliance
    of the implants and its subsequent conduct, I do not mean to suggest that
    because Health Canada’s conduct potentially increased the risk to Ms. Taylor
    that it necessarily created a relationship of proximity.  I agree with the
    observation in <em>Drady</em><em><span style='font-style:normal'>,</span></em> at paras. 44-62, that the fact that misrepresentations enhance the risk to
    users of the implants is not in and of itself germane to the proximity
    requirement.  That requirement must focus on the nature of the relationship
    between Health Canada and the users created by the misrepresentations taken in
    combination with Health Canada’s other conduct.  In my view, it is arguable
    that the misrepresentations, combined with the failure to correct that
    misrepresentation in the face of knowledge of the serious and ongoing risk
    posed to a clearly definable and relatively small group of consumers, could be viewed
    as akin to the regulator’s failure in <em>Fullowka</em> to act in the face of
    the known and ongoing dangers posed to the small and well-defined group of miners
    who worked in the specific mine which the regulator knew to be unsafe.  In <em>Fullowka</em>,
    the Supreme Court found sufficient proximity between the regulator and those
    miners to warrant the imposition of a private law duty of care: see also <em>Doe
    v. Metropolitan Toronto (Municipality) Commissioners of Police</em> (1990), 74
    O.R. (2d) 225 (H.C.J. Div. Ct.). </p>
  <p class=AParaNumbering>[112]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>No prior case is
    a perfect fit for this one, otherwise there would be no need to redo the
    proximity analysis. In <em>Fullowka</em>, the regulator was physically present
    in the mine on several occasions and was required by statute to directly
    regulate the conduct of the miners. Those features, which do not exist in this
    case, render the relationship between the regulator and the miners in <em>Fullowka</em> closer than the relationship between Health Canada and the recipients of the
    implants.</p>
  <p class=AParaNumbering>[113]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>Similarly, in <em>Doe</em>,
    the police were aware that the plaintiff was one of a handful of persons who
    had potentially been targeted by a serial rapist. The police were also under a
    specific statutory duty to prevent crime. That degree of specificity is not
    present on the facts as alleged in this case. </p>
  <p class=AParaNumbering>[114]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>Acknowledging,
    however, the factual differences among the cases, one should not ignore the
    similarities. In <em>Fullowka</em>, <em>Doe</em> and this case, the regulator
    failed to act to protect the life and safety of individuals when the regulator
    was fixed with knowledge of a clear, present and significant danger posed to a
    discrete and identifiable segment of the community. On these pleadings, there
    are the added features of a material misstatement by the regulator, a failure
    to correct that misstatement, a decision to refrain from notifying at least
    some of those individuals whom the regulator knew to be at risk as a result of
    the use of the implants, and a failure to adequately warn those whom Health
    Canada did notify of potential problems with the implants. It is arguable that
    those features of the case enhance Ms. Taylor’s proximity argument. </p>
  <p class=AParaNumbering>[115]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>I come next to the
    significance of allegations of representations made by the regulator and
    reliance placed on those representations by the plaintiff. No doubt, specific
    representations by a regulator to an individual, and reliance by that
    individual on those representations, will go a long way toward establishing a <em>prima
    facie</em> duty of care. The real issue here is whether that kind of direct representation
    and reliance is essential to a finding of a <em>prima facie</em> private law duty
    of care. If it is essential, Ms. Taylor has no claim as she does not allege
    that she was aware of, much less relied on, any of Health Canada’s
    representations concerning the safety of the implants.</p>
  <p class=AParaNumbering>[116]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>In <em>Drady</em>,
    after referring to several allegations in the pleadings in that case, including
    an allegation of the very misrepresentation in issue here, this court in
    holding that the pleadings did not reveal a cause of action, said, at para. 54:</p>
  <p class=CQuote>In the absence of a specific representation or reliance on
    Health Canada regarding the safety of the implant, in my view, it is plain and
    obvious that the appellant cannot establish a direct and close relationship of
    proximity that makes it just and fair to impose a private law duty of care on
    Health Canada.</p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[117]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em>The jurisprudence does not go so far as counsel for AG
    Canada suggests this passage does. The Supreme Court of Canada has imposed a <em>prima
    facie</em> private law duty of care on regulators in circumstances where there were
    no specific representations made to the plaintiff and no reliance on any
    specific representation by the plaintiff. <em>Hill</em><em><span
style='font-style:normal'> and</span></em> <em>Fullowka</em><em><span
style='font-style:normal'> are two examples. As repeatedly indicated in the
    Supreme Court of Canada jurisprudence, where a private law duty of care is said
    to arise from the specific relationship of the regulator and the plaintiff, the
    entirety of the circumstances said to constitute that relationship must be
    considered in determining whether that duty exists. </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[118]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>The nature of any representations
    made by the regulator, and the nature of any reliance placed on those
    representations by the plaintiff, are part of the entirety of the circumstances
    to be considered in determining the directness of the relationship between the
    regulator and the plaintiff. Representations made specifically to a plaintiff
    and relied on by that plaintiff can clearly forge a direct connection between
    the regulator and the plaintiff. General representations made by the regulator
    to the public and relied on by the plaintiff as a member of the public do not,
    standing alone, create a direct relationship. However, general representations
    and reliance on those representations can, in combination with other factors,
    create a relationship between the regulator and the plaintiff that is
    sufficiently close and direct to render it fair and just to impose on the regulator,
    in the conduct of its duties, an obligation to be mindful of the plaintiff’s
    legitimate interests.</span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[119]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>I would add that
    proximity is not necessarily an all-or-nothing proposition. Ms. Taylor advances
    different claims, as summarized above in para. 9. A trial judge could find a
    sufficiently close and direct relationship between Ms. Taylor and Health Canada
    to give rise to a </span></em><em>prima facie</em><em><span style='font-style:
normal'> duty of care in respect of some, but not all of the claims. For
    example, a trial judge might conclude that the relationship between Health
    Canada and Ms. Taylor at the time she received the implants did not give rise
    to a duty of care, but that the relationship had evolved into one of sufficient
    proximity to give rise to a duty of care by the time Health Canada discovered
    its misstatements with respect to the implants, became aware of the significant
    risks posed to individuals who had received the implants, and failed </span></em>either
    to notify implant recipients of the risks or to adequately advise those
    notified of the nature of the risks.  <em><span style='font-style:normal'>If a
    trial judge found that the relationship had in fact evolved into one justifying
    the imposition of a private law duty of care, then Health Canada may have
    breached that duty by failing to warn Ms. Taylor and other recipients of the ongoing
    danger presented by the implants so that Ms. Taylor and the others could take
    steps to mitigate the harm caused by the implants. </span></em></p>
  <p class=AParaNumbering><em><span
style='font-style:normal'>[120]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>Ultimately, I come to
    this point.  It is not clear to me that Ms. Taylor will at the end of the day
    succeed in making out a private law duty of care owed to her by Health Canada. 
    However, bearing in mind that at this stage the allegations must be assumed to
    be true and must be read generously, and also having regard to the dynamic
    nature of the jurisprudence, it is not plain and obvious that the claim as
    pleaded is bound to fail for want of a private law duty of care. The courtroom
    door cannot be closed to Ms. Taylor and the other members of the class at this
    stage. </span></em></p>
  <p class=MHeading12 style='page-break-after:
avoid'><em><span style='font-style:normal'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>VII<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></em><em><span style='font-style:normal'>&nbsp;</span></em></p>
  <h1>conclusion</h1>
  <p class=AParaNumbering style='page-break-after:
avoid'>[121]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>Question
    1 should be answered as proposed by counsel for AG Canada:</p>
  <p class=MsoListBullet2 style='line-height:200%'><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>The requirements for proximity are diverse and depend on the
    facts of each particular case.</p>
  <p class=AParaNumbering>[122]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>Question 2
    should be answered as follows:</p>
  <p class=MsoListBullet2 style='line-height:200%'><span style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>At this stage of the proceedings, it is not plain and obvious
    that the allegations in the Fresh Statement of Claim cannot support a finding
    that Health Canada owed the plaintiff a <em>prima facie</em> private law duty
    of care. </p>
  <p class=MHeading12><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>VIII<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>&nbsp;</p>
  <h1>remedy</h1>
  <p class=AParaNumbering>[123]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>Ms. Taylor is
    entitled to the remedy sought by her in the motion to determine a special case.
    The order of Cullity J., dated September 7, 2010, is affirmed. Ms. Taylor
    should be given a reasonable opportunity to reframe and streamline her
    pleadings in light of these reasons. </p>
  <p class=AParaNumbering>[124]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span>The parties may
    address the costs of this special case in written submissions of no more than four
    pages. Those submissions should be exchanged and filed within 45 days.</p>
  <p class=MsoBodyText>RELEASED:  “DD”  “JUL 06 2012”</p>
  <p class=MsoBodyText align=right style='text-align:right'>“Doherty J.A.”</p>
  <p class=MsoBodyText align=right style='text-align:right'>“I agree K.M. Weiler
    J.A.” </p>
  <p class=MsoBodyText align=right style='text-align:right'>“I agree John I.
    Laskin J.A.”</p>
  <p class=MsoBodyText align=right style='text-align:right'>“I agree Robert J.
    Sharpe J.A.”</p>
  <p class=MsoBodyText align=right style='text-align:right'>“I agree Robert P.
    Armstrong J.A.”</p>
</div>
<br clear=all>
<hr align=left size=1 width="33%">
<div id=ftn1>
  <p class=MsoFootnoteText><a href="#_ftnref1" name="_ftn1" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[1]</span></span></span></a> Health Canada is defined in the Fresh Statement of Claim as the various federal
    Ministers, departments and other entities responsible for regulating medical
    devices, including implants.</p>
</div>
<div id=ftn2>
  <p class=MsoFootnoteText><a href="#_ftnref2" name="_ftn2" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[2]</span></span></span></a> Of course, the claim contains only allegations, not facts. They are, however,
    accepted as true for the purposes of this exercise.</p>
</div>
<div id=ftn3>
  <p class=MsoFootnoteText><a href="#_ftnref3" name="_ftn3" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[3]</span></span></span></a> These regulations were replaced by a very different regulatory regime in 1998:
    see <em>Medical Devices Regulations</em>, SOR/98-282 (May 7, 1998).</p>
</div>
<div id=ftn4>
  <p class=MsoFootnoteText><a href="#_ftnref4" name="_ftn4" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[4]</span></span></span></a> The Fresh Statement of Claim (para. 15) refers to “Part V of the <em>Food and
    Drugs Act</em> which was enacted on April 1, 1983. There is no Part V of the <em>Food
    and Drugs Act</em>. The reference would appear to be to Part V of the <em>Medical
    Devices Regulations</em>. The reference to April 1, 1983 is also in error. Part
    V existed long before 1983.</p>
</div>
<div id=ftn5>
  <p class=MsoFootnoteText><a href="#_ftnref5" name="_ftn5" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[5]</span></span></span></a> The Fresh Statement of Claim treats April 1, 1983 as the operative date for
    determining whether the implants were “grandfathered” under the definition of
    “new device” in the applicable regulations. The discrepancy in the dates is
    irrelevant for present purposes.</p>
</div>
<div id=ftn6>
  <p class=MsoFootnoteText><a href="#_ftnref6" name="_ftn6" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[6]</span></span></span></a> I will use the word “regulator” interchangeably with the phrase “governmental
    body”.</p>
</div>
<div id=ftn7>
  <p class=MsoFootnoteText><a href="#_ftnref7" name="_ftn7" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[7]</span></span></span></a> See L. Klar, “<em><span style='font-style:normal'>The Tort Liability of Public
    Authorities: The Canadian Experience”</span></em> in S. Degeling, J. Edelman,
    &amp; J. Goudkamp, eds., <em>Torts in Commercial Law</em> (Australia: Thompson
    Reuters, 2011) Chap. 12.</p>
</div>
<div id=ftn8>
  <p class=MsoFootnoteText><a href="#_ftnref8" name="_ftn8" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[8]</span></span></span></a> Referring to <em>Anns v. Merton London Borough Council</em><span
style='font-size:11.0pt'>, [1978] A.C. 728 (U.K.H.L.).</span></p>
</div>
<div id=ftn9>
  <p class=MsoFootnoteText><a href="#_ftnref9" name="_ftn9" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[9]</span></span></span></a> The court went on to determine that the residual policy considerations at the
    second stage of the duty of care inquiry negated the existence of any duty of
    care owed by the regulator to the manufacturers.</p>
</div>
<div id=ftn10>
  <p class=MsoFootnoteText><a href="#_ftnref10" name="_ftn10" title=""><span
class=MsoFootnoteReference><span class=MsoFootnoteReference><span
style='font-size:10.0pt;font-family:"Arial","sans-serif"'>[10]</span></span></span></a> Arguments of proximity based on the regulator’s acknowledgement of its duties
    to the public and reliance on that acknowledgement seem close to the concept of
    “general reliance” discussed in the Australian cases, including cases like <em>Pyrenees
    Shire Council v. Day</em> (1998), 192 C.L.R. 330 (H.C.A.). To my knowledge, the
    concept of “general reliance” has not been adopted in any Canadian
    jurisdiction. See also <em>Gorringe v. Calderdale Metropolitan Borough Council</em>.</p>
</div>
</body>
</html>
